{"organizations": [], "uuid": "2f757236ce1ae892cdcfc9e5ea76a6b70df5b176", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/healthNews\r", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-therapix-bio-cannabis-study/israels-therapix-gets-positive-tourettes-drug-trial-results-idUSKBN1HG234", "country": "US", "domain_rank": 408, "title": "Israel's Therapix gets positive Tourette's drug trial results", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T17:03:00.000+03:00", "replies_count": 0, "uuid": "2f757236ce1ae892cdcfc9e5ea76a6b70df5b176"}, "author": "", "url": "https://www.reuters.com/article/us-therapix-bio-cannabis-study/israels-therapix-gets-positive-tourettes-drug-trial-results-idUSKBN1HG234", "ord_in_thread": 0, "title": "Israel's Therapix gets positive Tourette's drug trial results", "locations": [], "entities": {"persons": [{"name": "tourette", "sentiment": "negative"}, {"name": "adi zuloff-shani", "sentiment": "none"}, {"name": "ascher shmulewitz", "sentiment": "none"}], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "therapix", "sentiment": "none"}], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "therapix biosciences", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "JERUSALEM (Reuters) - Israel’s Therapix Biosciences announced positive results on Monday from a Phase IIa trial of its cannabinoid-based drug to treat Tourette syndrome (TS), sending its stock price jumping.\nThe clinical-stage pharmaceutical company said in a statement its drug candidate THX-110 “significantly improved symptoms over time” in adults with Tourette’s, which is characterised by involuntary movements and tics.\n“These results are of particular interest as the pharmacology of THX-110 appears to be distinct from existing medications for TS and may offer a unique option for treating these patients,” Chief Technology Officer Adi Zuloff-Shani said.\nCurrent available treatments are frequently inadequate or unsafe, she added.\nShares in Therapix were up 26 percent at $6.55 in pre-trading on Nasdaq.\nThe company is waiting for regulatory approval to begin a broader study, expanded to 40 subjects from 16, CEO Ascher Shmulewitz said.\nThe company has estimated the market opportunity in Tourette’s to be about $1.5 billion in the United States.\nThe same medicine is also being tested as a treatment for sleep apnea and pain management, Shmulewitz said.\nReporting by Ari Rabinovitch; Editing by Mark Potter\n ", "external_links": [], "published": "2018-04-09T17:03:00.000+03:00", "crawled": "2018-04-09T17:26:26.019+03:00", "highlightTitle": ""}